14.2 Clinical Studies in Adult and Pediatric Patients with Type 1 Diabetes Patients with inadequately controlled type 1 diabetes participated in a 24-week open-label, active-controlled study with a 28 week extension to evaluate the glucose lowering effect of once-daily BASAGLAR compared to that of once-daily administration of another insulin glargine product, 100 units/mL, or a non-U.S.-licensed insulin glargine, 100 units/mL, (comparator insulin glargine products, 100 units/mL) both in combination with mealtime insulin lispro
The global epidemiology of diabetes and kidney disease
delivery 4872 Hours Shipment protection Overnight shipping avail
In the SURPASS-4 trial, 15 mg weekly tirzepatide reduced the levels of total cholesterol, LDL cholesterol, and triglycerides by 5.6%, 7.9%, and 22.5%, respectively, and increased the levels of good cholesterol -HDL by 10.8% compared to placebo
Oscillations in microbial composition and activity generate time-of-daydependent patterns in key metabolites, many of which reach the liver through the portal circulation
